title: Biological drugs targeting the immune response in the therapy of psoriasis.
abstract: Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent behavior, gives a heavy burden to the patients' quality of life, and hence remains a huge medical and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. According to the current knowledge of the molecular and cellular basis of psoriasis, it is defined as an immune-mediated chronic inflammatory and hyperproliferative skin disease. A new generation of biological drugs, targeting molecules and cells involved into perturbed pro-inflammatory immune response in the psoriatic skin and joints, has been recently designed and applied clinically. These biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion proteins. In particular, they comprise the antitumor necrosis factor-alpha agents etanercept, infliximab, and adalimumab, with clinical efficacy in both moderate-severe psoriasis and psoriatic arthritis, and the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview recent findings on the molecular pathways relevant to the inflammatory response in psoriasis and present our clinical experience with the drugs currently employed in the dermatologic manifestations, namely etanercept, infliximab, and efalizumab. The growing body of clinical data on the efficacy and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.
authors.affiliation: Laboratory of Tissue Engineering and Cutaneous Physiopathology;
authors.forename: Saveria
authors.initials: S
authors.lastname: Pastore
authors.forename: Emanuela
authors.initials: E
authors.lastname: Gubinelli
authors.forename: Luca
authors.initials: L
authors.lastname: Leoni
authors.forename: Desanka
authors.initials: D
authors.lastname: Raskovic
authors.forename: Liudmila
authors.initials: L
authors.lastname: Korkina
references.citation: Semin Arthritis Rheum. 2005 Jun;34(6):819-36
references.pmid: 15942917
references.citation: Nature. 2007 Oct 4;449(7162):564-9
references.pmid: 17873860
references.citation: Lancet. 2007 Jul 21;370(9583):263-271
references.pmid: 17658397
references.citation: J Am Acad Dermatol. 2008 Jan;58(1):125-35
references.pmid: 17996329
references.citation: Curr Opin Investig Drugs. 2002 Nov;3(11):1590-5
references.pmid: 12476958
references.citation: N Engl J Med. 2003 Nov 20;349(21):2004-13
references.pmid: 14627785
references.citation: Health Qual Life Outcomes. 2006 Sep 27;4:71
references.pmid: 17005043
references.citation: J Am Acad Dermatol. 2004 Oct;51(4):580-4
references.pmid: 15389194
references.citation: Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):225-9
references.pmid: 16569361
references.citation: Cell. 2001 Feb 23;104(4):487-501
references.pmid: 11239407
references.citation: Expert Opin Ther Targets. 2005 Apr;9(2):225-43
references.pmid: 15934912
references.citation: Am J Pathol. 2003 Jan;162(1):203-11
references.pmid: 12507903
references.citation: Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632
references.pmid: 14676082
references.citation: JAMA. 2003 Dec 17;290(23):3073-80
references.pmid: 14679270
references.citation: J Am Acad Dermatol. 2006 Feb;54(2):361-2
references.pmid: 16443079
references.citation: Clin Dermatol. 2007 Nov-Dec;25(6):563-7
references.pmid: 18021893
references.citation: Lancet. 2007 Jul 21;370(9583):272-284
references.pmid: 17658398
references.citation: Br J Dermatol. 2005 Jun;152(6):1304-12
references.pmid: 15948997
references.citation: Br J Dermatol. 2006 Jan;154(1):194-5
references.pmid: 16729392
references.citation: Clin Rheumatol. 2007 Jul;26(7):1134-5
references.pmid: 17115099
references.citation: Expert Opin Investig Drugs. 2000 Mar;9(3):529-42
references.pmid: 11060693
references.citation: Clin Ther. 2005 Sep;27(9):1317-28
references.pmid: 16291408
references.citation: Arch Dermatol Res. 1998 May;290(5):240-5
references.pmid: 9681674
references.citation: J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98
references.pmid: 16922950
references.citation: J Drugs Dermatol. 2006 Jun;5(6):546-8
references.pmid: 16774108
references.citation: JAMA. 2006 May 17;295(19):2275-85
references.pmid: 16705109
references.citation: J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S154-63
references.pmid: 16488337
references.citation: J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15
references.pmid: 17097378
references.citation: Arch Dermatol. 2007 Aug;143(8):1053-7
references.pmid: 17709665
references.citation: Arch Dermatol Res. 2006 Jun;298(1):7-15
references.pmid: 16691429
references.citation: Lancet. 2005 Oct 15-21;366(9494):1367-74
references.pmid: 16226614
references.citation: Dermatol Clin. 2007 Apr;25(2):207-13, vii
references.pmid: 17430757
references.citation: Arch Dermatol. 2005 Jan;141(1):31-8
references.pmid: 15655139
references.citation: J Dtsch Dermatol Ges. 2006 Nov;4(11):947-56
references.pmid: 17081270
references.citation: Nature. 2002 Jun 20;417(6891):861-6
references.pmid: 12075355
references.citation: Br J Dermatol. 2006 Jul;155(1):170-81
references.pmid: 16792770
references.citation: Br J Dermatol. 2005 Sep;153(3):486-97
references.pmid: 16120132
references.citation: Arch Dermatol Res. 2006 Dec;298(7):329-38
references.pmid: 17021768
references.citation: Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):175-83
references.pmid: 15180471
references.citation: N Engl J Med. 2003 Nov 20;349(21):2014-22
references.pmid: 14627786
references.citation: Nature. 2007 Oct 4;449(7162):551-3
references.pmid: 17873861
references.citation: J Cell Sci. 2003 Dec 1;116(Pt 23):4695-705
references.pmid: 14600256
references.citation: Nat Clin Pract Rheumatol. 2007 Mar;3(3):156-64
references.pmid: 17334338
references.citation: N Engl J Med. 2002 Oct 10;347(15):1151-60
references.pmid: 12374875
references.citation: J Am Acad Dermatol. 2003 Jun;48(6):829-35
references.pmid: 12789171
references.citation: Genes Immun. 2007 Jan;8(1):1-12
references.pmid: 17093502
references.citation: J Am Acad Dermatol. 2004 Oct;51(4):534-42
references.pmid: 15389187
references.citation: Lancet. 2001 Jun 9;357(9271):1842-7
references.pmid: 11410193
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S112-9
references.pmid: 16488321
references.citation: N Engl J Med. 1979 Sep 6;301(10):555
references.pmid: 460314
references.citation: Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):594-8
references.pmid: 1731329